Study #2024-1865
A phase 3, randomized, double-blind, placebo-controlled study of optune (TTFields, 200 kHz) concomitant with maintenance temozolomide and pembrolizumab versus optune concomitant with maintenance temozolomide and placebo for the treatment of newly diagnosed glioblastoma (EF-41/KEYNOTE D58)
MD Anderson Study Status
Enrolling
Treatment Agent
Temozolomide, Pembrolizumab, Placebo
Description
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Glioblastoma
Study phase:
Phase III
Physician name:
Chirag Patel
Department:
Neuro-Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.